Guobang Pharma Ltd. (SHA:605507)

Guobang Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,586	1,909	2,094	1,974	893.01	1,235
Trading Asset Securities	746.17	617.66	465.99	824.56	1,258	0.03
Cash & Short-Term Investments	2,332	2,527	2,560	2,799	2,151	1,235
Cash Growth	-2.05%	-1.29%	-8.52%	30.09%	74.24%	-2.38%
Accounts Receivable	1,548	1,332	964.92	775.34	571.5	544.51
Other Receivables	24.12	17.97	17.22	21.07	45.03	30.83
Receivables	1,572	1,350	982.14	796.41	616.53	575.34
Inventory	1,440	1,363	1,369	1,409	1,309	989.55
Prepaid Expenses	-	-	-	-	0.7	-
Other Current Assets	916.66	634.05	532.31	125.15	489.48	71.64
Total Current Assets	6,261	5,874	5,443	5,129	4,567	2,871
Property, Plant & Equipment	4,290	4,344	4,330	3,284	2,622	2,152
Long-Term Investments	110.61	112.57	121.13	101.37	17.11	18.67
Goodwill	0.03	0.03	0.03	0.03	0.03	0.03
Other Intangible Assets	348.34	350.83	358.85	370.5	272.26	266.71
Long-Term Deferred Tax Assets	8.74	8.96	7.78	6.59	19.02	12.01
Long-Term Deferred Charges	7.33	7.45	8.02	9.26	2.6	3.37
Other Long-Term Assets	88.06	82.64	92.64	142.61	12.79	184.52
Total Assets	11,115	10,780	10,362	9,043	7,513	5,509
Accounts Payable	1,592	1,704	1,715	974.35	789.71	1,096
Accrued Expenses	58.29	125.97	97.06	107.06	100.47	86.68
Short-Term Debt	373.14	181.23	488.79	664.28	168.88	518.12
Current Portion of Long-Term Debt	342.61	452.17	28.88	-	-	150.25
Current Income Taxes Payable	42.63	22.47	18.44	4.26	30.24	23.57
Current Unearned Revenue	40.15	39.93	55.85	52.79	30.68	42.71
Other Current Liabilities	42.91	32.34	45.99	59.64	33.53	55.39
Total Current Liabilities	2,492	2,558	2,450	1,862	1,154	1,972
Long-Term Debt	337.37	146.72	451.7	-	-	251
Long-Term Unearned Revenue	18.19	16.67	11.8	14.27	9.71	8.27
Long-Term Deferred Tax Liabilities	7.8	7.2	11.32	11.93	4.16	2.69
Total Liabilities	2,855	2,728	2,924	1,889	1,167	2,234
Common Stock	558.82	558.82	558.82	558.82	558.82	475
Additional Paid-In Capital	3,609	3,609	3,607	3,607	3,607	1,047
Retained Earnings	4,096	3,881	3,266	2,989	2,180	1,753
Treasury Stock	-8.52	-1.48	-	-	-	-
Total Common Equity	8,255	8,047	7,432	7,155	6,346	3,275
Minority Interest	4	4.72	5.15	-0.65	-0.39	-0.58
Shareholders' Equity	8,259	8,052	7,437	7,155	6,346	3,274
Total Liabilities & Equity	11,115	10,780	10,362	9,043	7,513	5,509
Total Debt	1,053	780.12	969.37	664.28	168.88	919.37
Net Cash (Debt)	1,279	1,747	1,591	2,134	1,982	315.27
Net Cash Growth	-2.30%	9.81%	-25.46%	7.66%	528.79%	12.17%
Net Cash Per Share	2.28	3.13	2.86	3.82	3.87	0.67
Filing Date Shares Outstanding	565.73	558.37	555.51	558.82	558.82	475
Total Common Shares Outstanding	565.73	558.74	558.82	558.82	558.82	475
Working Capital	3,769	3,317	2,994	3,267	3,414	898.7
Book Value Per Share	14.59	14.40	13.30	12.80	11.36	6.89
Tangible Book Value	7,907	7,696	7,073	6,785	6,074	3,008
Tangible Book Value Per Share	13.98	13.77	12.66	12.14	10.87	6.33
Buildings	-	1,812	1,706	1,025	810.75	717
Machinery	-	3,980	3,372	2,487	1,933	1,646
Construction In Progress	-	255.26	636.65	874.85	827.46	571.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.